[Long-term suppression of acid secretion with omeprazole use in metastatic gastrinoma].
We report on the clinical signs, diagnosis and 8-year course in a 54-year-old female patient with myeloma and gastrinoma with liver metastasis and associated Cushing syndrome treated for the last 3 years with the new H+/K+-ATPase inhibitor omeprazole which has successfully suppressed the massive gastric acid hypersecretion.
Schaub
N
N
Medizinische Klinik, Kantonsspital Bruderholz, Liestal.
Schlup
M
M
Kummer
H
H
Wegmann
W
W
D005260:Female; D005750:Gastric Juice / Q000378:metabolism; D015408:Gastrinoma / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000556:secondary; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary; D009853:Omeprazole / Q000494:pharmacology / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D010954:Plasmacytoma / Q000150:complications*
D009853:Omeprazole
Langzeitsuppression der Säuresekretion durch Omeprazol bei einem metastasierenden Gastrinom.